Jaguar Health reports positive preliminary results from crofelemer study
Preliminary results from an open-label study in adults with short bowel syndrome with intestinal failure were presented at the annual American College of Gastroenterology meeting.
Story updates
01:06:45 PM UTC
SquawkNews
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF and microvillus inclusion disease (MVID) for crofelemer powder for oral solution, targeting a mid-2027 NDA filing for MVIDSAN FRANCISCO, CA / / October 14, 2026 / Jag…